The new pattern of medicine is gradually forming, and pharmaceutical companies with innovative and cost-control capabilities are favored.

"Pharmaceutical Network Market Analysis" August 7, Shanghai issued a notice to encourage public hospitals not included in the national and municipal procurement of drugs into the scope of centralized bargaining procurement.
industry analysis that, with the third batch of national harvesting and local collection of the promotion, means that the normalization of collection and harvesting began, the pharmaceutical industry gradually formed a new pattern, there will be more over-evaluated drugs will be included in the collection.
For the winning drug companies, in the short term, a large amount of market share may be exchanged for low prices, but for companies that already have a large market share, the collected drugs in the market share at the same time, there may be a decline in revenue."
For such pharmaceutical companies, look at the product pipeline, if the pharmaceutical companies have other heavy products to keep up, it will not be too affected;
for the original market share is not high, but successfully winning the bid of pharmaceutical companies, especially small and medium-sized enterprises, is a "bend over the car" a good opportunity.
long term, the winning enterprises in the market share increase at the same time, with the gradual appearance of the scale effect, the drug continues to release, the profit of future sales will continue to improve.
as far as the winning enterprise is concerned, for the product market cake can only "see", can not "share food", obviously not conducive to the long-term development of enterprises.
industry veterans believe that, under the new pattern of the pharmaceutical industry, pharmaceutical companies with product innovation and cost control capabilities will be optimistic, including Zhongsheng Pharmaceuticals, Pharmaceuticals and other leading.
, Zhongsheng Pharmaceuticals has strong innovation ability, and a rich product line, with a number of heavy-duty products.
as of August 5, the company had approved applications for 20 new products and adaptive disorders, achieving 67% of its target for this year.
industry expects more than 30 new products and adaptations to be approved each year over the next three years, and potential collaborations with innovative pharmaceutical companies and CRO companies are expected to further enrich the research and development product line.
industry analysis pointed out that the third batch of collection on the impact of Chinese medicine neutral or even positive.
that the company has 12 drugs involved in the third round of national drug collection, five of which are 19 years and this year by the new drug application (ANDA) approved varieties.
that centralized procurement effectively replaces drug bidding and has a neutral impact on the Future of the Group.
, Which said in a research report that The company will report its first-half results at the end of the month, with revenue expected to grow in units, in line with market expectations.
pharmaceutical industry has been working to improve the scale of technology platform capacity-building, accelerate the discovery and development of biological drugs to commercial production of the whole process.
's research and development spending reached 6.5 percent of total revenue in 2019, with WuXiBody and ADC, two technology platforms, signing 13 and 9 new projects in 2019, respectively. during the
reporting period, the Group's Antibody Conceding Drug Primary Liquids and Preparations Plant (DP3) invested in the commercial production of GMP and reached an in-depth strategic cooperation agreement with Zhejiang Pharmaceutical Subsidiary New Code Bio, to further support phase III clinical research and large-scale commercial production of the new code bioADC candidate drug ARX788.
13 of the 28 antibody drug association (ADC) projects being developed on the Group platform have progressed to the New Drug Clinical Trial Application (IND) phase.
company issued a positive earnings forecast in the early hours of July 29th, predicting that profits attributable to shareholders of the company's equity in the first half of 2020 would increase by more than 58% year-on-year.
also said in June that it expected first-half revenue growth of about 10 per cent.
In response to the reasons for the increase in profits, Pharmaceuticals said in its announcement that the Group has an effective business continuity plan to minimize the impact of public health events on its business and operations;
.